Trius Therapeutics Completes Enrollment in Second Phase 3 Trial of Tedizolid for Skin and Skin Structure Infections

Trius Therapeutics Completes Enrollment in Second Phase 3 Trial of Tedizolid for Skin and Skin Structure Infections

[at noodls] – SAN DIEGO, Dec. 10, 2012 (GLOBE NEWSWIRE) — Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for life-threatening … more

View todays social media effects on TSRX

View the latest stocks trending across Twitter. Click to view dashboard

See who Trius is hiring next, click here to view

Share this post